News and Trends 2 Jun 2023 von Willebrand disease treatment gets FDA orphan drug designation The U.S. Food and Drug Administration (FDA) has granted Vega Therapeutics, Inc. orphan drug designation for its antibody therapy, VGA039, for the treatment of the rare bleeding disorder, von Willebrand… June 2, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2023 Acepodia raises $100M financing to boost cell therapies Acepodia, a clinical stage biotechnology company developing first-in-class cell therapies with its antibody-cell conjugation (ACC) and allogeneic gamma delta 2 T-cell platforms to address gaps in cancer care, has announced… June 8, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2017 Janssen’s Psoriasis Drug is Given a Thumbs Up for Use in Europe …3-10% or more than 10% of the body is affected. Guselkumab (Tremfya) is a human anti-IL-23 monoclonal antibody developed by Janssen and generated using MorphoSys’s Human Combinatorial Antibody Library (HuCAL)… November 23, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2022 Integral Molecular joins FDA’s ISTAND program …by allowing them to be used in regulatory (IND, NDA or BLA) applications without needing the FDA to reconsider and reconfirm their suitability. Integral Molecular said antibodies and antibody-based therapies,… September 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 7 Nov 2023 Eight biotech companies tackling infectious diseases head-on …is because new virus variants are constantly emerging and because antibody responses to vaccines wane over time, demanding vaccines that target different COVID strains. Gritstone bio Another contender tapping into… November 7, 2023 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jun 2023 Astellas developing new gastric cancer drug …antibody, for first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive. If approved, zolbetuximab would be the first… June 9, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 8 Oct 2024 Top biotech deals of September 2024 …bispecific antibody to its immunotherapy pipeline. The deal amount was undisclosed. Biotech deals by approach in September 2024 The business of RNA therapeutics Among all the major deals signed last month,… October 8, 2024 - 6 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 2 Jun 2025 Top biotech deals in May 2025 …further and potentially commercialize them. Besides, Taiwanese company Formosa Pharmaceuticals and Northern Ireland-based Almac Discovery have begun a collaboration over antibody-drug conjugates (ADCs). Formosa will gain control of Almac’s solid… June 2, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 16 Dec 2022 Alchemab Therapeutics receives £1.7M grant to work on therapy for Huntington’s disease …to accelerate development of our antibody and deliver some hope for patients.” This is the second grant awarded to Alchemab and MDC. The financing will support preclinical development of the… December 16, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Mar 2019 Blocking Hidden Viral Protein Shows Promise for Treating Multiple Sclerosis An antibody that blocks the action of a hidden viral protein encoded by our genome shows encouraging signs of slowing down the progression of multiple sclerosis, according to the Swiss… March 12, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 15 Oct 2020 Swiss Biotech Launches Amidst Hot Streak for Rare Autoimmune Disease …there were no approved treatments for neuromyelitis optica. That year, Alexion Pharmaceuticals’ Soliris, a monoclonal antibody targeting the complement protein C5, was approved for the treatment of this condition by… October 15, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Startup Scout 31 May 2019 This Biotech Treats a Neurological Autoimmune Disorder Using DNA …begin clinical trials in 2023. Pure Biologics also has a separate program developing an antibody drug that binds two targets at once, called a bispecific antibody. Although there are other… May 31, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email